Patents Assigned to Indevus Pharmaceutical, Inc.
-
Patent number: 7842303Abstract: This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises: 1. a reservoir, said reservoir comprising; 2. at least one active ingredient; and, optionally, 3. at least one pharmaceutically acceptable carrier; a polyurethane based polymer completely surrounding the reservoir.Type: GrantFiled: August 10, 2004Date of Patent: November 30, 2010Assignee: Indevus Pharmaceuticals, Inc.Inventors: Sheng-hung Kuo, Petr Kuzma
-
Patent number: 7553847Abstract: The present invention provides methods for treating social anxiety disorder, comprising administering 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone or 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-5-hydroxy-2-oxohexyl) -1-isoindolinone or pharmaceutically acceptable salt, or optical isomer therof, and optionally comprising administering another compound for the treatment of social anxiety disorder that is a GABA agonist.Type: GrantFiled: February 13, 2006Date of Patent: June 30, 2009Assignee: Indevus Pharmaceuticals, Inc.Inventors: Cathryn M. Clary, Jeroen Van Beek, Perry S. Eisman, Sean Donevan, Atul Pande, Richard Kavoussi, Lyou-Fu Ma
-
Patent number: 7510549Abstract: A device for inserting implantable objects beneath the skin of a patient includes a handle for grasping the device and a base connected to the handle. The base comprises a post, a cannula, and a flexible actuator positioned in an angled track. The cannula is positioned coaxially around and is longitudinally slidable over the post from an extended position, where an implantable object is retained in the cannula, to a retracted position, where the implantable object is released from the cannula. A flexible actuator positioned on an angled track in the base is slidably engaged with a boss on the cannula and is used to move the cannula from an extended position to a retracted position to release the implantable object from the cannula; the actuator flexes between a locked and an unlocked position. The angled track provides for control of the release of the implantable object.Type: GrantFiled: September 13, 2006Date of Patent: March 31, 2009Assignee: Indevus Pharmaceutical, Inc.Inventors: Matthew L. Rue, David S. Tierney
-
Patent number: 7452868Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.Type: GrantFiled: March 10, 2006Date of Patent: November 18, 2008Assignee: Indevus Pharmaceuticals, Inc.Inventors: Petr Kuzma, Stephanie Decker
-
Publication number: 20080182892Abstract: The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses (6aR,10aR)-?8-tetrahydrocannabinol-11-oic acids (hereinafter referred to as (6aR,10aR)-?8-THC-11-oic acid), as well as pharmaceutical compositions containing the (6aR,10aR)-?8-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention further covers methods of formulating and administering the compounds and pharmaceutical compositions as therapeutic agents in the treatment of interstitial cystitis, with particularly preferred administration routes being oral and via intravesicular instillation.Type: ApplicationFiled: February 15, 2008Publication date: July 31, 2008Applicant: Indevus Pharmaceuticals, Inc.Inventors: Bobby W. Sandage, Glenn L. Cooper
-
Patent number: 7304158Abstract: The present invention relates to methods for making racemic 2-(7-chloro -1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-1-isoindolinone and (+)-2-(7 -chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone.Type: GrantFiled: April 27, 2006Date of Patent: December 4, 2007Assignee: Indevus Pharmaceuticals, Inc.Inventors: Sandra Marie Jennings, Timothy Lee Stuk
-
Publication number: 20060128738Abstract: The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses cannabinol analogs, which are preferably analogs of (6aR,10aR)-?8-tetrahydrocannabinol-11-oic acids [hereinafter referred to as (6aR,10aR)-?8-THC-11-oic acid], as well as pharmaceutical compositions containing the cannabinol analogs and analogs of (6aR,10aR)-?8-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention further covers methods of formulating and administering the compounds and pharmaceutical compositions as therapeutic agents in the treatment of interstitial cystitis, with particularly preferred administration routes being oral and via intravesicular instillation.Type: ApplicationFiled: December 13, 2005Publication date: June 15, 2006Applicant: Indevus Pharmaceuticals, Inc.Inventors: Bobby Sandage, Glenn Cooper
-
Publication number: 20060128794Abstract: The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses (6aR,10aR)-?8-tetrahydrocannabinol-11-oic acids (hereinafter referred to as (6aR,10aR)-?8-THC-11-oic acid), as well as pharmaceutical compositions containing the (6aR,10aR)-?8-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention further covers methods of formulating and administering the compounds and pharmaceutical compositions as therapeutic agents in the treatment of interstitial cystitis, with particularly preferred administration routes being oral and via intravesicular instillation.Type: ApplicationFiled: December 13, 2005Publication date: June 15, 2006Applicant: Indevus Pharmaceuticals, Inc.Inventors: Bobby Sandage, Glenn Cooper
-
Patent number: 7057047Abstract: The present invention relates to methods for making racemic 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-1-isoindolinone and (+)-2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone.Type: GrantFiled: August 18, 2005Date of Patent: June 6, 2006Assignee: Indevus Pharmaceuticals, Inc.Inventors: Sandra Marie Jennings, Timothy Lee Stuk
-
Patent number: 7026332Abstract: Methods of treating obsessive-compulsive disorder comprising administering 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone are disclosed.Type: GrantFiled: April 25, 2002Date of Patent: April 11, 2006Assignee: Indevus Pharmaceuticals, Inc.Inventors: Cathryn M. Clary, Jeroen Van Beek, Perry S. Eisman, Sean Donevan, Atul Pande, Richard Kavoussi, Lyou-Fu Ma
-
Publication number: 20050288322Abstract: The present invention relates to methods for making racemic 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-1-isoindolinone and (+)-2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone.Type: ApplicationFiled: August 18, 2005Publication date: December 29, 2005Applicant: Indevus Pharmaceuticals, Inc.Inventors: Sandra Jennings, Timothy Stuk
-
Patent number: 6974835Abstract: The invention relates to the use of cannabinoid compounds (derivatives of tetrahydrocannabinol) for decreasing cell proliferation in a mammal.Type: GrantFiled: May 17, 2001Date of Patent: December 13, 2005Assignee: Indevus Pharmaceuticals, Inc.Inventors: Sumner Burstein, Lawrence Recht, Robert B. Zurier
-
Publication number: 20050256029Abstract: Methods of treating stuttering include treating people with gamma-aminobutyric acid (GABA) receptor modulators, including cyclopyrrolones. A second active agent may be used with GABA receptor modulators. Active enantiomers, active metabolites, and pharmaceutically acceptable salts of gamma-aminobutyric acid receptor modulators, including cyclopyrrolones, are acceptable components of the compositions. The cyclopyrrolone class of modulators includes pagoclone, suriclone, zopiclone, 2-(7-chloro-2-naphthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one, 2-(7-chloro-2-naphthyridin-1,8-yl)isoindolin-1-yl-4-acetamidobutyrate, and 2-(7-chloro-1,8-naphthyridin-2yl)-3-(5-methyl-5-hydroxy-2-oxohexyl)-1-isoindolinone.Type: ApplicationFiled: February 1, 2005Publication date: November 17, 2005Applicant: Indevus Pharmaceuticals, Inc.Inventors: John Murphy, Kay D'Orlando
-
Publication number: 20050232983Abstract: A transdermal delivery system for pyrrole derivatives of formula 1, metabolites thereof, enantiomers thereof, racemates thereof, and salts including acid addition salts thereof, alone or in conjunction with one or more other therapeutic agents, using vehicles selected to enhance absorption and which enable the compounds to be administered into and through the skin when topically applied.Type: ApplicationFiled: April 12, 2005Publication date: October 20, 2005Applicant: INDEVUS PHARMACEUTICALS, INC.Inventor: Bobby Sandage
-
Patent number: 6953670Abstract: The present invention relates to a variant from of the receptor for the obese gene product. In particular, the invention relates to methods of detecting this receptor variant in cells and tissues of obese individuals. In addition, it relates to methods of inhibiting or down regulating expression of this variant in cells to augment their responsiveness to weight regulation by leptin as well as methods of using compounds to directly activate signal transduction pathways associated with this ligand-receptor system. In addition, the invention relates to identifying compounds capable of supplementing biological activity of leptin on cells expressing a leptin receptor variant.Type: GrantFiled: September 17, 2002Date of Patent: October 11, 2005Assignee: Indevus Pharmaceuticals, Inc.Inventors: H. Ralph Snodgrass, Joseph Cioffi, Thomas Joel Zupancic, Alan Wayne Shafer
-
Patent number: 6949653Abstract: The present invention relates to methods for making racemic 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-1-isoindolinone and (+)-2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone.Type: GrantFiled: March 27, 2003Date of Patent: September 27, 2005Assignee: Indevus Pharmaceuticals, Inc.Inventors: Sandra Marie Jennings, Timothy Lee Stuk
-
Patent number: 6914072Abstract: The invention relates to the use of cannabinoid compounds (derivatives of tetrahydrocannabinol) for decreasing cell proliferation in a mammal.Type: GrantFiled: May 17, 2001Date of Patent: July 5, 2005Assignee: Indevus Pharmaceuticals, Inc.Inventors: Sumner Burstein, Lawrence Recht, Robert B. Zurier
-
Patent number: 6855721Abstract: Methods of treating stuttering include treating people with gamma-aminobutyric acid (GABA) receptor modulators, including cyclopyrrolones. A second active agent may be used with GABA receptor modulators. Active enantiomers, active metabolites, and pharmaceutically acceptable salts of gamma-aminobutyric acid receptor modulators, including cyclopyrrolones, are acceptable components of the compositions. The cyclopyrrolone class of modulators includes pagoclone, suriclone, zopiclone, 2-(7-chloro-2-naphthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one, 2-(7-chloro-2-naphthyridin-1,8-yl)isoindolin-1-yl-4-acetamidobutyrate, and 2-(7-chloro-1,8-naphthyridin-2y1)-3-(5-methyl-5-hydroxy-2-oxohexyl)-1-isoindolinone.Type: GrantFiled: July 28, 2000Date of Patent: February 15, 2005Assignee: Indevus Pharmaceuticals, Inc.Inventors: John J. Murphy, Kay Jorgenson D'Orlando
-
Patent number: 6838079Abstract: The present invention relates to methods for using various forms of a novel receptor expressed by hematopoietic and endothelial cells. An additional variant form of this receptor has been detected in brain cells and shown to bind to the obese gene product, leptin. Therefore, leptin may be used to stimulate the growth and development of receptor-positive hematopoietic and endothelial cells in vitro and in vivo. In addition, this receptor is selectively expressed in hematopoietic progenitor cells with long-term repopulating potential. Thus, agents that specifically bind to this receptor may be used to identify and isolate progenitor cells for a variety of clinical applications.Type: GrantFiled: March 12, 2002Date of Patent: January 4, 2005Assignee: Indevus Pharmaceuticals, Inc.Inventors: H. Ralph Snodgrass, Joseph Cioffi, Thomas Joel Zupancic, Alan Wayne Shafer
-
Patent number: 6524806Abstract: The present invention relates to a novel member of the hematopoietin receptor family, herein referred to as Hu-B1.219. In particular, the invention relates to nucleotide sequences and expression vectors encoding Hu-B1.219 gene product. Genetically engineered host cells that express the Hu-B1.219 coding sequence may be used to evaluate and screen for ligands or drugs involved in Hu-B1.219 interaction and regulation. Since Hu-B1.219 expression has been detected in certain human fetal tissues and cancer cells, molecular probes designed from its nucleotide sequence may be useful for prenatal testing and cancer diagnosis.Type: GrantFiled: July 19, 1999Date of Patent: February 25, 2003Assignee: Indevus Pharmaceuticals, Inc.Inventors: H. Ralph Snodgrass, Joseph Cioffi, Thomas Joel Zupancic, Alan Wayne Shafer